Clinical trials: Drug Reaction
Kidney Transplantation, Transplantation Immunology
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
- Conditions
- Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction
- Trial name
- NCT00717678
- Testing
- Prograf-XL, Prograf, MMF
- Where
- 5 sites in Taiwan
- Volunteers
- 73 people
- Sponsor
- Astellas Pharma Inc
Contrast Enhanced X-ray Based Examination
A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
This is an observational study in which patient data from the past of people who received Ultravist prior to an X-ray based scan are studied.
- Trial name
- NCT05428397
- Testing
- Iopromide (Ultravist, BAY86-4877)
- Where
- Germany
- Volunteers
- 152,233 people
- Sponsor
- Bayer
No Protrusion, No Open Wound
The Sponsor Assigns Test Products to Six Skin Areas According to a Concealed Randomization Schedule; Neither the Evaluating Physicians Nor the Participants Know Which Product is Applied to Which Site, Preventing Bias.
This is a single-center, double-blind, randomized, and controlled study. The sponsor keeps the allocation of products to the six test sites confidential.
- Conditions
- No Protrusion, No Open Wound, No Severe Allergic Reaction, No Scar
- Trial name
- NCT07154004
- Testing
- Test Serum 897222 210, Test Serum 897222 212, Test Serum 897250 39
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BEIJING YUANBEN INFORMATION CONSULTING CO., LTD
Diagnostic Agent Adverse Reaction, Radiation Exposure
18F-LY3950321-01 Biodistribution and Safety Study
18F-LY3950321 (also known as 18F-MNI-1256) is a radiolabeled positron emission tomography (PET) tracer targeting granzyme B. The overall goal of this protocol is to evaluate the safety, tolerability, and radiation dosimetry of…
- Trial name
- NCT05775601
- Testing
- 18F-LY3950321, PET Scan
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Drug Reaction to Analgesic Nos
Topical Anesthetic for Procedures Through the Nose
To determine if RX0041-002 is a safe and effective topical anesthetic.
- Trial name
- NCT02667054
- Testing
- RX0041 4%, RX0041 8%
- Where
- 2 sites in United States
- Volunteers
- 648 people
- Sponsor
- Pharmaceutical Project Solutions, Inc.
Parkinson's Disease, Dyskinesia
Capturing Parkinson's Disease Medication Side Effects During Daily Activities
The purpose of the study is to test whether body-worn wireless motion sensors can measure dyskinesias (involuntary movements caused by medications) in individuals with Parkinson disease (PD) independent of voluntary activity…
- Trial name
- NCT01429207
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
HIV Infections
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV
This study will evaluate the tolerability and acceptability of injection site reactions (ISRs) of two long-acting (LA) injectables.
- Trial name
- NCT06970223
- Testing
- Cabotegravir long-acting, Lenacapavir long-acting
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Tumor Infiltrating Lymphocytes, Safety
A Study of GC101 TIL in Advanced Melanoma (BZ)
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 20 months.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Melanoma, Efficacy
- Trial name
- MIZAR-002 (NCT06120712)
- Testing
- GC101 TIL
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Drug Hypersensitivity
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase.
- Trial name
- NCT00198458
- Testing
- Vitrase
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Type 2 Diabetes Mellitus
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
10 healthy volunteers will be enrolled to each receive two subcutaneous injections of ISIS 113715 in the abdomen on Study Day 1. Each subject will receive their two injections within a 5-minute period.
- Trial name
- NCT00365781
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Genetics of Drug Metabolism
Pharmacogenomic Testing Of the Elderly To Reduce Morbidity
The goal of the POETRY Registry is to determine whether data from Pharmacogenomic (PGx) Testing for elderly and disabled patients can help physicians manage patient medication regimens and assess if the testing has an effect on…
- Trial name
- POETRY (NCT02095769)
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 280,000 people
- Sponsor
- General Genetics Corporation
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
COVID, Drug Effect
Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications
This retrospective cohort study will include eligible patients that received a positive COVID-19 test and filled a new prescription for one of the repurposed medications (including hydroxychloroquine, chloroquine, with or without…
- Conditions
- COVID, Drug Effect, Drug Interaction, Risk Reduction
- Trial name
- NCT04432350
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Adverse Reaction to Drug
Post-market Safety Reassessment of Ulinastatin for Injection
1. Investigate the application of ulinastatin(UTI) in real practice clinic.(eg:population character, usage and dosage, course of treatment,etc ) 2.
- Trial name
- NCT02520570
- Testing
- ulinastatin
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Techpool Bio-Pharma Co., Ltd.
Localized Adverse Reaction to Administration of Drug
Intralymphatic eASC Administration in Healthy Volunteers
The objective is to determine the safety, tolerability and feasibility of the inguinal intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)
- Trial name
- NCT01743222
- Testing
- eASC
- Where
- Spain
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Tigenix S.A.U.
Communicable Disease Transmission, Zoonotic Disease
A Bridging Study of the SYN023 on Healthy Adult Subjects
The Phase I bridging clinical trial is to evaluate on the safety, pharmacokinetics (PK), pharmacodynamics (PD) and ADA of a single intramuscular injection of recombinant anti-rabies human monoclonal antibody injection (SYN023)…
- Conditions
- Communicable Disease Transmission, Zoonotic Disease, Rabies Human, Vaccine Reaction
- Trial name
- NCT04495569
- Testing
- recombinant anti-rabies human monoclonal antibody injection (SYN023), Rabies Vaccine
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers.
- Trial name
- PER977-P1 (NCT01826266)
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Polypharmacy Patients
Assessment of a Novel Algorithm System for Polypharmacy Patient Medication Safety and Consultation
The aim of this study is to determine if insights based on the analysis of historical data of multidrug patients' electronic health records, by a novel system and algorithm, is noninferior to a clinical pharmacist analysis and…
- Trial name
- NCT05589870
- Testing
- Multi-drug analysis of polypharmacy treatment
- Where
- Israel
- Volunteers
- 91 people
- Sponsor
- MDI Health
Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
The primary purpose of the study is to investigate the incidence of adverse drug reactions (ADRs) (ADR of special interest: capillary leak syndrome, infusion reaction, rhabdomyolysis, myelosuppression, infection, hepatic…
- Trial name
- NCT05137847
- Testing
- Remitoro
- Where
- 3 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Eisai Inc.
COVID, Drug Effect
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in a health insurance…
- Conditions
- COVID, Drug Effect, Drug Interaction, Adverse Drug Event
- Trial name
- NCT04378881
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Tabula Rasa HealthCare